AstraZeneca is set to invest $50 billion in the U.S., featuring a large manufacturing plant in Virginia, marking its biggest manufacturing investment. This move aligns with the company’s expectation that 50% of its revenue will come from the U.S. by 2030. The decision comes amid rising tariff pressures from the Trump administration, aiming to bolster domestic drug supply chains.